Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer

Purpose: To identify a predictive molecular “signature” for sensitivity to retinoic acid in pancreatic cancer. Experimental Design: Fourteen patient-derived, low-passage pancreatic ductal adenocarcinoma (PDAC) lines with varied expression of fatty acid–binding protein 5 (FABP5) and cellular retinoic acid–binding protein 2 (CRABP2) were used to evaluate the response to all-trans retinoic acid (ATRA). Cell proliferation, apoptosis, and migration/invasion assays were used to measure the in vitro response. Tumor growth was monitored in subcutaneous xenografts in athymic nude mice for 4 weeks. Results: Response to ATRA was observed to be dependent upon differential expression of FABP5 versus CRABP2. Thus, elevated FABP5 expression was associated with minimal cytotoxicity and tumor growth inhibition and a paradoxical increase in migration and invasion. Conversely, CRABP2 expression in the absence of FABP5 was associated with significant tumor growth inhibition with ATRA, even in gemcitabine-resistant tumors. The ATRA-resistant phenotype of FABP5highCRABP2null cells could be circumvented by ectopic expression of CRABP2. Alternatively, reexpression of endogenous CRABP2 could be enabled in FABP5highCRABP2null PDAC lines by exposure to decitabine and trichostatin A, thereby relieving epigenetic silencing of the CRABP2 gene promoter. Immunohistochemical staining for FABP5 in archival human tissue microarrays identifies a subset of cases (13 of 63, ∼20%) which are negative for FABP5 expression and might be candidates for ATRA therapy. Conclusions: The widely used agent ATRA deserves a “second look” in PDAC, but needs to be targeted to patient subsets with biopsy-proven FABP5-negative tumors, or be combined with a chromatin-modifying agent to reexpress endogenous CRABP2. Clin Cancer Res; 18(1); 280–9. ©2011 AACR.

[1]  R. Moss,et al.  Oncotargets and Therapy Dovepress Current and Emerging Therapies for the Treatment of Pancreatic Cancer , 2022 .

[2]  C. Iacobuzio-Donahue,et al.  Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. , 2007, Cancer research.

[3]  N. Noy,et al.  Retinoic Acid Is a High Affinity Selective Ligand for the Peroxisome Proliferator-activated Receptor β/δ* , 2003, Journal of Biological Chemistry.

[4]  S. Lippman,et al.  Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. , 1995, American journal of clinical oncology.

[5]  Fredy Sussman,et al.  Ligand recognition by RAR and RXR receptors: binding and selectivity. , 2005, Journal of medicinal chemistry.

[6]  T. Adrian,et al.  Natural retinoids inhibit proliferation and induce apoptosis in pancreatic cancer cells previously reported to be retinoid resistant , 2005, Cancer biology & therapy.

[7]  A. Dalgleish,et al.  13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  Padmamalini Kannan-Thulasiraman,et al.  Involvement of Fatty Acid Binding Protein 5 and PPARβ/δ in Prostate Cancer Cell Growth , 2010, PPAR research.

[9]  J. Eshleman,et al.  Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma , 2011, Clinical Cancer Research.

[10]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[11]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[12]  T. Schug,et al.  Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR , 2008, Proceedings of the National Academy of Sciences.

[13]  T. Adrian,et al.  High concentrations of retinoids induce differentiation and late apoptosis , 2005, Cancer biology & therapy.

[14]  G. Kroemer,et al.  Quantitation of mitochondrial alterations associated with apoptosis. , 2002, Journal of immunological methods.

[15]  M. Goggins,et al.  Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.

[16]  K. Ohuchida,et al.  All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. , 2005, Cancer letters.

[17]  A. Camargo,et al.  Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. , 2009, Neoplasia.

[18]  T. Schug,et al.  Opposing Effects of Retinoic Acid on Cell Growth Result from Alternate Activation of Two Different Nuclear Receptors , 2007, Cell.

[19]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[20]  B. Ohlsson,et al.  The Expression of Retinoic Acid Receptors and the Effects in Vitro by Retinoids in Human Pancreatic Cancer Cell Lines , 2002, Pancreas.

[21]  D. Levinthal,et al.  Distinct Roles for Cellular Retinoic Acid-binding Proteins I and II in Regulating Signaling by Retinoic Acid* , 1999, The Journal of Biological Chemistry.

[22]  Peng Liu,et al.  Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription , 2002, Molecular and Cellular Biology.

[23]  Satish K. Tickoo,et al.  Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model , 2005, Clinical Cancer Research.

[24]  N. Mongan,et al.  Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies , 2010, Cancer biology & therapy.

[25]  T. Nakagawa,et al.  Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. , 2009, Cancer letters.

[26]  Hans Clevers,et al.  Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. , 2011, Gastroenterology.

[27]  Lucia Altucci,et al.  The promise of retinoids to fight against cancer , 2001, Nature Reviews Cancer.

[28]  M R Cullen,et al.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. , 1996, Journal of the National Cancer Institute.